We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
Read MoreHide Full Article
Key Takeaways
Beta Bionics secured FDA clearance for Mint, marking its entry into the tubeless patch pump market.
BBNX plans full U.S. commercialization of Mint in Q1 2027, with pharmacy-channel distribution.
Beta Bionics cut 2026 revenue guidance to $121-$126M as customers may delay purchases before Mint's launch.
Beta Bionics, Inc. (BBNX - Free Report) recently secured FDA clearance for its Mint patch pump, marking a key milestone in expanding its automated insulin delivery portfolio. The company also unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review. The company outlined commercialization timelines for both innovations.
The clearance strengthens Beta Bionics' long-term growth story by opening the door to the fast-growing patch pump market and supporting broader pharmacy channel adoption. Although the company trimmed its 2026 revenue outlook due to expected purchase delays ahead of Mint's launch, management expects the product to drive growth in 2027 and support a stronger long-term margin profile as production scales.
Likely Trend of BBNX Stock Following the News
Following the announcement, shares of BBNX surged more than 15% in yesterday’s trading. Year to date, shares of the company have lost 27.2% compared with the industry’s 8.1% decline. However, the S&P 500 has risen 10.6% in the same timeframe.
The FDA clearance of Mint is likely to strengthen Beta Bionics' long-term business by expanding its reach beyond traditional tubed insulin pumps into the fast-growing patch pump market, potentially increasing its addressable customer base. The upcoming 3D Intelligence algorithm could further enhance product differentiation by offering greater personalization across both iLet and Mint platforms, while the pharmacy-channel launch strategy may improve patient access and recurring disposable revenue over time.
As manufacturing scales and coverage expands, the company could benefit from higher adoption and improved profitability over the longer term.
BBNX currently has a market capitalization of $865.2 million.
Image Source: Zacks Investment Research
Mint Patch Pump Expands Beta Bionics' Diabetes Platform
Mint marks Beta Bionics' entry into the tubeless patch pump market, complementing its existing iLet automated insulin delivery platform and broadening patient choice across hardware options. The FDA-cleared device features a two-piece reusable and disposable architecture that eliminates the need for recharging while supporting seamless patch replacement without phone re-pairing, firmware-over-the-air updates and smartphone control on both iOS and Android.
The patch pump is designed for three days of wear with an additional 12-hour grace period and includes a 200-unit insulin reservoir. It is compatible with Dexcom G7, Dexcom G7 15 Day and Abbott's FreeStyle Libre 3 Plus CGMs, positioning the platform for broad interoperability. Beta Bionics also expects Mint 3D, powered by its next-generation 3D Intelligence algorithm pending FDA clearance, to launch alongside the full commercial rollout, giving clinicians multiple algorithm options tailored to individual patient needs.
3D Intelligence Adds Another Growth Catalyst
Beta Bionics also introduced 3D Intelligence, its next-generation insulin dosing algorithm, and confirmed that it has been submitted to the FDA through the 510(k) pathway. Building on real-world experience from more than 40,000 iLet users, the software is expected to offer Original, Optimized and Conservative algorithm experiences, allowing clinicians to better match insulin delivery behavior to individual patient requirements while preserving the platform's automated approach.
Subject to regulatory clearance, the company expects to commercialize iLet 3D by the end of 2026, with Mint 3D launching alongside the full U.S. rollout of Mint in the first quarter of 2027. The dual-platform strategy could strengthen Beta Bionics' competitive positioning by combining multiple hardware form factors with greater software personalization.
Updated Outlook Reflects Near-Term Tradeoff for Future Growth
Beta Bionics lowered its full-year 2026 revenue guidance to $121-$126 million from the previous $131-$136 million, citing the possibility that prospective iLet customers may delay purchases ahead of Mint's launch. Management expects any fourth-quarter revenue deferral to be recaptured during 2027 as Mint enters full commercialization. Gross margin guidance for 2026 remains unchanged at 58.5%-59.5%, while Mint is expected to be modestly dilutive to margins next year before becoming highly accretive as production scales.
The company expects to begin full U.S. commercialization of Mint in the first quarter of 2027, earlier than previously targeted, with manufacturing capacity of at least 1.5 million disposable units during the year and the potential for higher output through automation and efficiency gains.
Mint is likely to launch exclusively through the pharmacy channel, where roughly 40% of insured U.S. lives are expected to have initial access, with coverage anticipated to expand to at least 50% within the first year.
Per a report by Grand View Research, the global insulin patch pumps market size was estimated at USD 912.5 million in 2022 and is anticipated to expand at a CAGR of 10.9% from 2023 to 2030.
The high growth can primarily be attributed to factors such as technological advancements, the rising prevalence of diabetes and increasing awareness regarding advanced patch pumps.
Other News
Recently, BBNX reported its second-quarter 2026 results, with net sales rising 38% year over year to $32 million, driven by a 153% surge in Pharmacy Benefit Plan channel sales to $11.6 million and a 9% increase in Durable Medical Equipment channel sales to $20.4 million. Although the company posted an operating loss of $25.6 million, the loss improved as a percentage of sales to 80% from 86% in the year-ago quarter.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
Key Takeaways
Beta Bionics, Inc. (BBNX - Free Report) recently secured FDA clearance for its Mint patch pump, marking a key milestone in expanding its automated insulin delivery portfolio. The company also unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review. The company outlined commercialization timelines for both innovations.
The clearance strengthens Beta Bionics' long-term growth story by opening the door to the fast-growing patch pump market and supporting broader pharmacy channel adoption. Although the company trimmed its 2026 revenue outlook due to expected purchase delays ahead of Mint's launch, management expects the product to drive growth in 2027 and support a stronger long-term margin profile as production scales.
Likely Trend of BBNX Stock Following the News
Following the announcement, shares of BBNX surged more than 15% in yesterday’s trading. Year to date, shares of the company have lost 27.2% compared with the industry’s 8.1% decline. However, the S&P 500 has risen 10.6% in the same timeframe.
The FDA clearance of Mint is likely to strengthen Beta Bionics' long-term business by expanding its reach beyond traditional tubed insulin pumps into the fast-growing patch pump market, potentially increasing its addressable customer base. The upcoming 3D Intelligence algorithm could further enhance product differentiation by offering greater personalization across both iLet and Mint platforms, while the pharmacy-channel launch strategy may improve patient access and recurring disposable revenue over time.
As manufacturing scales and coverage expands, the company could benefit from higher adoption and improved profitability over the longer term.
BBNX currently has a market capitalization of $865.2 million.
Image Source: Zacks Investment Research
Mint Patch Pump Expands Beta Bionics' Diabetes Platform
Mint marks Beta Bionics' entry into the tubeless patch pump market, complementing its existing iLet automated insulin delivery platform and broadening patient choice across hardware options. The FDA-cleared device features a two-piece reusable and disposable architecture that eliminates the need for recharging while supporting seamless patch replacement without phone re-pairing, firmware-over-the-air updates and smartphone control on both iOS and Android.
The patch pump is designed for three days of wear with an additional 12-hour grace period and includes a 200-unit insulin reservoir. It is compatible with Dexcom G7, Dexcom G7 15 Day and Abbott's FreeStyle Libre 3 Plus CGMs, positioning the platform for broad interoperability. Beta Bionics also expects Mint 3D, powered by its next-generation 3D Intelligence algorithm pending FDA clearance, to launch alongside the full commercial rollout, giving clinicians multiple algorithm options tailored to individual patient needs.
3D Intelligence Adds Another Growth Catalyst
Beta Bionics also introduced 3D Intelligence, its next-generation insulin dosing algorithm, and confirmed that it has been submitted to the FDA through the 510(k) pathway. Building on real-world experience from more than 40,000 iLet users, the software is expected to offer Original, Optimized and Conservative algorithm experiences, allowing clinicians to better match insulin delivery behavior to individual patient requirements while preserving the platform's automated approach.
Subject to regulatory clearance, the company expects to commercialize iLet 3D by the end of 2026, with Mint 3D launching alongside the full U.S. rollout of Mint in the first quarter of 2027. The dual-platform strategy could strengthen Beta Bionics' competitive positioning by combining multiple hardware form factors with greater software personalization.
Updated Outlook Reflects Near-Term Tradeoff for Future Growth
Beta Bionics lowered its full-year 2026 revenue guidance to $121-$126 million from the previous $131-$136 million, citing the possibility that prospective iLet customers may delay purchases ahead of Mint's launch. Management expects any fourth-quarter revenue deferral to be recaptured during 2027 as Mint enters full commercialization. Gross margin guidance for 2026 remains unchanged at 58.5%-59.5%, while Mint is expected to be modestly dilutive to margins next year before becoming highly accretive as production scales.
The company expects to begin full U.S. commercialization of Mint in the first quarter of 2027, earlier than previously targeted, with manufacturing capacity of at least 1.5 million disposable units during the year and the potential for higher output through automation and efficiency gains.
Mint is likely to launch exclusively through the pharmacy channel, where roughly 40% of insured U.S. lives are expected to have initial access, with coverage anticipated to expand to at least 50% within the first year.
Beta Bionics, Inc. Price
Beta Bionics, Inc. price | Beta Bionics, Inc. Quote
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global insulin patch pumps market size was estimated at USD 912.5 million in 2022 and is anticipated to expand at a CAGR of 10.9% from 2023 to 2030.
The high growth can primarily be attributed to factors such as technological advancements, the rising prevalence of diabetes and increasing awareness regarding advanced patch pumps.
Other News
Recently, BBNX reported its second-quarter 2026 results, with net sales rising 38% year over year to $32 million, driven by a 153% surge in Pharmacy Benefit Plan channel sales to $11.6 million and a 9% increase in Durable Medical Equipment channel sales to $20.4 million. Although the company posted an operating loss of $25.6 million, the loss improved as a percentage of sales to 80% from 86% in the year-ago quarter.
BBNX’s Zacks Rank & Key Picks
Currently, BBNX has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.